Alemtuzumab can be Incorporated Into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Phase I Results of a Cancer and Leukemia Group B Study (CALGB 10102)
- Citation:
- Blood vol 114 (22) 345-345
- Meeting Instance:
- ASH 2009
- Year:
- 2009
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- None
- Pharmas:
- Grants:
- Corr. Author:
- Authors:
- W. Stock B. Sanford G. Lozanski R. Vij J. C. Byrd B. L. Powell M. Wetzler D. Sher C. Edwards M. Kelly S. Richards C. Sung G. Malnassy E. Hoke C. D. Bloomfield R. A. Larson
- Networks:
- Study
- CALGB-10102
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 1/2
- Keywords: